© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
New Data Show Safety of Ado-Trastuzumab, Trastuzumab Biosimilars in HER2+ Cancers
Skylar Jeremias
June 11 2024
Posters from the American Society of Clinical Oncology annual meeting showcased safety and efficacy data for a trastuzumab biosimilar and an ado-trastuzumab biosimilar in HER2-positive (HER2+) cancers.
Dr Lakesha Farmer Highlights Current Biosimilar Education, Acceptance Efforts
Ashley Gallagher,Skylar Jeremias
June 9 2024
Cencora's Lakesha Farmer, PharmD, MBA, discusses efforts that health care organizations can take to better educate patients and providers on biosimilars to improve biosimilar acceptance and achieve cost savings associated with these products.
Posters Capture Clinical Impacts of Infliximab in Super-Responders, Pregnant Patients With IBD
Skylar Jeremias
June 1 2024
Posters from Digestive Disease Week 2024 look at how super-responders and pregnant patients with inflammatory bowel disease (IBD) react to treatment with subcutaneous infliximab and an infliximab biosimilar, respectively.
Posters Demonstrate Switching Safety Between Originator, Biosimilar Infliximab in IBD
Skylar Jeremias
May 23 2024
Two posters from Digestive Disease Week found that switching patients with inflammatory bowel disease (IBD) from Remicade to an infliximab biosimilar did not impact clinical outcomes, with one study focusing on switches in pediatric patients and the other focusing on patients undergoing multiple switches.
DDW 2024 Posters Evaluate Safety, Efficacy, Impact of BMI on Zymfentra Use
Skylar Jeremias
May 21 2024
Posters from Digestive Disease Week (DDW) on the ongoing LIBERTY-CD trial assessing Zymfentra, a subcutaneous infliximab product, compared with intravenous infliximab treatment in Crohn disease show the safety and efficacy of the product, as well as the impact of body mass index (BMI) on clinical outcomes.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
Skylar Jeremias
May 19 2024
The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Data Show Promise for Adalimumab Biosimilars to Deliver on Safety, Cost Savings
Skylar Jeremias
May 16 2024
Two posters from the Academy of Managed Care Pharmacy’s annual meeting provided hope that despite low uptake so far, adalimumab biosimilars can deliver on the promise of comparable safety and efficacy with the originator in multiple disease states, as well as cost savings.
Panelists Call for Consistent Education, Support to Improve Patient Comfort With Biosimilars
Skylar Jeremias
May 15 2024
At the Festival of Biologics USA, panelists stressed the need for patient-centered communication and education to boost comfort with biosimilars, emphasizing consistent support from health care providers despite restrictive payer policies.
Cencora Analysis Shows Differences in Payer Coverage Between G-CSF Biosimilars
Skylar Jeremias
May 2 2024
AMCP: Academy of Managed Care Pharmacy
Data from a Cencora study showed some misalignment in payer coverage of granulocyte colony-stimulating factor (G-CSF) biosimilars, highlighting that while filgrastim biosimilars are often favored over the originator, reference pegfilgrastim still dominates over its biosimilars.